Five-year denosumab treatment of postmenopausalwomen with osteoporosis: results of the first twoyears of the freedom trial extension.

Five-year denosumab treatment of postmenopausalwomen with osteoporosis: results of the first twoyears of the freedom trial extension.

Bibliographic Details
Main Authors:	S Papapoulos, Z Man, D Mellstrom, S Radominski, J-Y Reginster, H Resch, J Roman, S Roux, S Cummings, H Bone, R Chapurlar, M Brandi, J Brown, E Czerwinski, N Daizadeh, A Grauer, M-A Krieg, S Libanati
Format:	Article
Language:	English
Published:	Endocrinology Research Centre 2011-04-01
Series:	Остеопороз и остеопатии
Online Access:	https://endojournals.ru/index.php/osteo/article/view/4135

Similar Items

Influence of subject discontinuation on long-term nonvertebral fracture rate in the denosumab FREEDOM Extension study
by: Jonathan D. Adachi, et al.
Published: (2017-04-01)

Targeted approaches in the treatment of osteoporosis: differential mechanism of action of denosumab and clinical utility
by: Cavalli L, et al.
Published: (2012-06-01)

Similarities and Differences in the Management of Patients with Osteoporotic Vertebral Fractures and Those with Rebound-Associated Vertebral Fractures Following Discontinuation of Denosumab
by: Athanasios D. Anastasilakis, et al.
Published: (2023-09-01)

Denosumab for the treatment of osteoporosis
by: Michael R. McClung
Published: (2017-03-01)

Clinical results of combination therapy with teriparatide and denosumab
by: Imoto Yuki, et al.
Published: (2017-09-01)

Efficacy of denosumab in two cases with multiple-system atrophy and osteoporosis
by: Uehara M, et al.
Published: (2018-05-01)

Should denosumab treatment for osteoporosis be continued indefinitely?
by: Jane A. Noble, et al.
Published: (2021-04-01)

Denosumab-Induced Immune Hepatitis
by: Viviana Ostrovsky, et al.
Published: (2021-01-01)

Advantages of using denosumab for osteoporosis
by: O. B. Ershova, et al.
Published: (2013-12-01)

Denosumab: A comprehensive review
by: Prasad Narayanan
Published: (2013-01-01)

Cost-utility of denosumab for the treatment of postmenopausal osteoporosis in Spain
by: Darbà J, et al.
Published: (2015-02-01)

Secondary organising pneumonia caused by denosumab
by: Djalaleddine Ouakidi, et al.
Published: (2023-09-01)

A review of denosumab for the treatment of osteoporosis
by: Miyazaki T, et al.
Published: (2014-04-01)

Osteoporosis in men: epidemiology and treatment with denosumab
by: Sidlauskas KM, et al.
Published: (2014-04-01)

Use of Denosumab in a rheumatology centre
by: Hazlyna Baharuddin, et al.
Published: (2017-09-01)

Four-Year Teriparatide Followed by Denosumab vs. Continuous Denosumab in Glucocorticoid-Induced Osteoporosis Patients With Prior Bisphosphonate Treatment
by: Yasuaki Hirooka, et al.
Published: (2021-09-01)

Safety of denosumab in dialysis patients on calcium and vitamin D supplements
by: Asad Ullah, et al.
Published: (2017-01-01)

Severe, Symptomatic Hypocalcemia due to Denosumab Administration: Treatment and Clinical Course
by: Jarred Strickling, et al.
Published: (2019-04-01)

Denosumab and bisphosphonates: different mechanisms of action and effects.
by: Baron, R, et al.
Published: (2011)

Current indications for denosumab in benign bone tumours
by: Antal Imre, et al.
Published: (2023-12-01)

Denosumab, an effective osteoporosis treatment option for men
by: Sung Hye Kong
Published: (2022-09-01)

Long-term consequences of osteoporosis therapy with denosumab
by: Francisco Bandeira, et al.
Published: (2022-12-01)

The efficacy of denosumab in Korean male patients with osteoporosis
by: Chaiho Jeong, et al.
Published: (2022-09-01)

Denosumab to treat CGCG: A case report
by: Akbar Rezaie, et al.
Published: (2022-06-01)

Denosumab for the prevention of osteoporotic fractures in postmenopausal women
by: N Waugh, et al.
Published: (2011-05-01)

Safety of denosumab in patients with chronic kidney disease
by: Nasra K Al Adhoubi, et al.
Published: (2021-01-01)

Efficiency of denosumab in giant cell tumor of the bone
by: N N Semenov
Published: (2013-06-01)

Safety and tolerability of denosumab for the treatment of postmenopausal osteoporosis
by: Lewiecki EM
Published: (2011-12-01)

Update on Denosumab Treatment in Postmenopausal Women with Osteoporosis
by: Yong-Ki Min
Published: (2015-03-01)

Denosumab treatment in patients with different courses of osteoporosis
by: Liudmila Ya. Rozhinskaya, et al.
Published: (2017-12-01)

Impact of denosumab on bone mass in cancer patients
by: Brown-Glaberman U, et al.
Published: (2013-07-01)

Safety and efficacy of denosumab in postmenopausal somen with osteoporosis
by: Dilsad Sindel, et al.
Published: (2020-10-01)

Denosumab-induced alopecia areata with lichenoid eruption
by: Mohsen Dourra, MD, et al.
Published: (2021-11-01)

Osteoporosis Therapy With Denosumab in Organ Transplant Recipients
by: Jana Brunova, et al.
Published: (2018-04-01)

THE USE OF DENOSUMAB IN GIANT CELL TUMORS IN THE SACRUM
by: PEDRO LUIS BAZÁN, et al.

The use of neo - adjuvant denosumab in treatment of giant cell tumours of the spine
by: Beresford-Cleary, N, et al.
Published: (2022)

Ludin’s <i>Kopftuch</i> (headdress): A problem of religious freedom in German schools
by: P.H. Coetzee, et al.
Published: (2004-07-01)

EFFICACY OF DENOSUMAB RELATIVE TO OTHER OSTEOPOROSIS THERAPIES FOR PREVENTION OF FRACTURES IN POSTMENOPAUSAL OSTEOPOROSIS: RESULTS OF AN ADJUSTED INDIRECT AND MIXED TREATMENT COMPARISON
by: Freemantle, N, et al.
Published: (2010)

Aggressive osteoblastoma with a secondary aneurysmal bone cyst treated with denosumab
by: Karlton Wong, et al.
Published: (2021-08-01)

Denosumab Discontinuation and the Rebound Phenomenon: A Narrative Review
by: Athanasios D. Anastasilakis, et al.
Published: (2021-01-01)